Local drugmakers lag behind in R&D spending

Korean drug companies are still lagging far behind their overseas counterparts in research and development (R&D) investment, spawning fears that they will lose out.

Aggressive R&D investment has been the main driver for their robust performance, which is said to have played a role in transforming domestic drug firms into world-class makers.

However, contrary to this widely-held perception...